Long noncoding RNA PANDAR inhibits the development of lung cancer by regulating autophagy and apoptosis pathways

Lan Zhang1*, Yuanhang Wang2*, Shengyuan Xia1, Lei Yang3, Di Wu4, Yifeng Zhou5, Jiachun Lu3✉

1. Department of Medical Genetics and Cell Biology, GMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, China.
2. Jiaxing Center for Disease Control and Prevention, Jiaxing, China.
3. The State Key Lab of Respiratory Disease, The First Affiliated Hospital, The institute for Chemical Carcinogenesis, School of Public health, Guangzhou Medical University, Guangzhou, China.
4. Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
5. Department of Genetics, Medical College of Soochow University, Suzhou, China.

*Lan Zhang and Yuanhang Wang contributed equally to this work.

✉Corresponding author: Jiachun Lu, The State Key Lab of Respiratory Disease, The First Affiliated Hospital, The institute for Chemical Carcinogenesis, School of Public health, Guangzhou Medical University, Xinzao Town, Panyu District, Guangzhou, 511436, China. Tel +86 20 37104661; Fax +86 20 37104661; E-mail jclu@gzhmu.edu.cn

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.02.25; Accepted: 2020.05.24; Published: 2020.06.06

Abstract

**Background:** LncRNAs has been shown to play important roles in the progression of lung cancer, but it remains poorly understood whether lncRNAs affect the occurrence and development of lung cancer by regulating autophagy and apoptosis levels. Here, we investigated the roles of PANDAR in NSCLC.

**Materials and Methods:** The expression profile and clinical application of PANDAR and its possible target gene BECN1 were tested in 276 cases of lung cancer tissues. Through some actual experiments, we explored functions of PANDAR about proliferation, apoptosis and autophagy of NSCLC cells in vitro.

**Results:** PANDAR was found to downregulate both in lung cancer tissues and cell lines compared with corresponding controls (P < 0.05 for all), which was related to tumor stage (P < 0.05). Moreover, autophagy related gene BECN1 was also downregulated in lung cancer tissues comparison with normal tissues (P < 0.01), and there was a significant positive correlation between PANDAR and BECN1 levels (r = 0.789, P < 0.001). So, the high expression of PANDAR increased BECN1 expression levels and impaired the proliferation of NSCLC cell lines in vitro. Furthermore study showed PANDAR could regulate cell autophagy and apoptosis levels.

**Conclusion:** These results indicated lncRNA PANDAR was a tumor suppressor and can inhibit NSCLC cell proliferation by activating autophagy and apoptosis pathways via upregulation of BECN1 expression.

Key words: PANDAR, BECN1, lung cancer, autophagy, apoptosis

Introduction

Lung cancer remains the main factor of deaths due to carcinoma over the years[1]. The leading reason for poor treatment of lung cancer is many cases have reached an advanced stage [2]. NSCLC was nearly 80 per cent among lung cancer patients and makes up to the majority of cancer deaths [3]. Although, survival rate of lung cancer has improved with the development in chemotherapy, surgical techniques and molecular targeted therapies, the 5-year survival rate of advanced patients is still less than 5% [4]. The reason for that is the unclear molecular mechanism. Therefore, a detailed elaboration on the mechanisms is indispensable for improving the diagnosis, prevention and treatment of NSCLC.

Autophagy is an intracellular catabolic and recycled process with lysosome-mediated [5]. Theoretically, autophagy promotes survival by
eliminating cells of toxic metabolites, damaged organelles, intracellular pathogens or by excessive self-digestion and degradation of elementary cell compositions, but it is not known whether autophagy regulates cellular survival or death pathway or both [6]. So far, researchers have indicated that autophagy is closely associated with the progression of NSCLC [7, 8]. For example, BECN1 with encoding Beclin1 protein is a specific gene for autophagy [9]. Numerous studies have indicated that BECN1 is not only involved in the formation of autophagosome, but also influences the development of lung cancer by regulating cell autophagy levels [10].

LncRNA has no protein-coding ability but it could regulate gene expression [11]. It involves in biological processes of diverse cancers including NSCLC [12-14]. For example, some papers have revealed that lncRNAs are closely related to the formation, development, migration and metastasis of NSCLC, particularly MEG3, HOTAIR, FENDRR and others [15-17]. Moreover, some studies have concluded that lncRNAs expression patterns in NSCLC are involved in the expression of thousands of genes concurrently [18, 19]. LncRNAs can act a pivotal part in NSCLC progression through a great deal of signaling pathways [20]. However, to date, the mechanisms and molecular pathways in NSCLC are not largely elucidated. Therefore, identification of NSCLC-associated lncRNAs and investigation of the functions and mechanism are useful for improving diagnosis and treatment in NSCLC. Lately, Hung et al. have proved that PANDAR is interacted with transcription factor to limit pro-apoptotic genes expression [21]. Han et al. concluded the low expression PANDAR can predict poor prognosis and affected apoptosis by regulating Bcl-2 in NSCLC [22]. Pattingre et al. clarified the Bcl-2 functioned as an anti-apoptotic and anti-autophagy protein via interaction with Beclin1 [23]. Our early research results have demonstrated that the Beclin1 protein expression decreased in malignant transformation of 16HBE cells, indicating that autophagy acted a critical part in the development of lung cancer [24]. Nowadays majority of evidences emphasize the roles of lncRNAs by the apoptotic pathways in cancer. There is little report about the relationship between lncRNAs and cell autophagic function in NSCLC. Thus, it is explored whether lncRNA PANDAR can play a significant biological role by regulating BECN1 expression and investigated potential mechanisms of PANDAR in NSCLC.

In this research, we investigated the expression profile and clinical application of lncRNA PANDAR and possible target gene BECN1 in lung cancer tissues. Experiments were performed to test the functions of lncRNA PANDAR on proliferation, apoptosis and autophagy of NSCLC cells in vitro.

Materials and Methods

Tissue collection

All subjects were Han Chinese in China. 276 lung cancer tissues and normal lung tissues were gathered from patients with pathologically diagnosed primary lung cancer. The cases had not received chemotherapy, radiation or immunotherapy prior to surgery. Among these, 182 samples were obtained from the First Affiliated Hospital and Cancer Center of Guangzhou Medical University, the Cancer Hospital of Kunming Medical University in southern China. 94 samples were collected from the First Affiliated Hospital of Soochow University in eastern China. All samples involved in the study had no genetic relationship with each other. All tissues were stored at −80°C in liquid nitrogen.

Cell lines and culture conditions

The 16HBE and human NSCLC cell lines (L78, PC9, 95D, NCI-H460, A549) were purchased from Shanghai Institute of Cell Biology. These cells were cultured in RPMI-1640 medium with 10 per cent FBS and penicillin/streptomycin with 5 per cent carbon dioxide at 37°C.

RNA extraction and qRT-PCR

Total RNA was extracted from tissues and cells using TRIzol reagent. First-strand cDNA was synthesized with PrimeScript RT reagent Kit. qRT-PCR were used to detecte the expression of PANDAR and BECN1 using SYBR Green Mixture with ROX, BIOMIGA and gene specific primers. Data was collected on ABI 7900. β-actin was selected as an internal reference gene to normalize results, and all primer sequences were as follows. β-actin (forward: GGCGGCCACCACTGTACCT; reverse: AGGGGC CGGACTCTCATACT), PANDAR (forward: TCCCAAAACAGGCTTTG; reverse: GTGGCCAAAG GATCTGACGA), BECN1 (forward: TGGCAAACTC AATAACTTGAG; reverse: GACCCATCTTATGGG CCAGA), GAPDH (forward: AGCCATACGTCGTCA GACG), GAPDH (forward: TGGCACCTGACGAG ACAC; reverse: GCCCAATACGAAGAATCC), U6 (forward: CTCGCTTCGGAGCTGTCA; reverse: AAGCC TCTCAGAACATTTC).

Subcellular fractionation

To explore cellular localization of PANDAR, cytosolic and nuclear fractions were collected using nuclear/cytoplasmic isolation kit. We examined the expression of PANDAR using qRT-PCR, GAPDH and U6 in cytoplasm and nuclear fractions. GAPDH and
U6 were used as cytosolic and nuclear fraction indicators respectively.

**Plasmid construction**

The sequence of PANDAR control were synthesized and subcloned into pEZ-Lv206 from GeneCopoeia, Guangzhou, China. The ectopic expression of PANDAR was obtained using the pEZ-Lv206-PANDAR transfection, and empty pEZ-Lv206 particles was used as a control group. The resulting construct was verified by sequencing from Sangon Biotech, Shanghai, China.

**Cell transient transfection**

Cell lines were transfected with pEZ-LV206-PANDAR, pEZ-LV206-control and extracted with Plasmid Midiprep System, Promega. PC9 and A549 cells were cultured for 24 h and transfected into six-well plate using Lipofectamine3000. The transfected cell lines were harvested after 48 h or 72 h for follow-up series of cell assays. Besides, the experimental methods of two plasmid co-transfection were same as above.

**Western blot analysis and antibodies**

Western blot analysis was used for examining protein expression. The cells were collected and lysed using RIPA buffer supplemented with protease inhibitors. BECN1 and LC3 were the detecting antibodies. GAPDH was used as the housekeeping gene. All antibodies, including Beclin1, LC3, GAPDH and HRP-linked secondary antibody (Rabbit) were from CST.

**Cell proliferation assays**

The effects of upregulated PANDAR about proliferation in A549 and PC9 cells were tested with CCK8. 24 hours after transfection with pEZ-LV206-PANDAR or control, cells were collected and seeded 1000 cells per well in 96-well plates. From a period, CCK8 was added in at least five replicate wells and incubated for 1-4 hours at 37°C. OD was measured at 450 nm by a plate reader.

**Morphological examination of apoptotic cells**

PC9 and A549 were treated as indicated and incubated for 48 hours, and stained with Hoechst 33258 for 30 min at 37°C in the dark. Fluorescence images of normal and apoptotic cells were examined under fluorescence microscope.

**Detection of BECN1 release**

In order to determine the main pathway of PANDAR inducing apoptosis by regulating BECN1 expression, PC9 and A549 cells were co-transfected with DsRed-Mit and GFP-BECN1. The experimental group cells were treated by apoptosis promoter EBSS (Sigma-Aldrich, Germany), and the control group cells did not any treatment, and then imaged by the fluorescence microscope. We obtained images of GFP-BECN1 and DsRed-Mit respectively, and then merged them. The images of GFP-BECN1 and DsRed-Mit were obtained separately and then merged. The BECN1 released from mitochondria was determined based on the overlap of GFP-BECN1 and DsRed-Mit fluorescence images.

**Statistical analysis**

T-test was used to evaluate the discrepancy in gene expression between two groups Statistical analysis was conducted with Stata 12.0 software. A two sided value of $P < 0.05$ was considered having statistical significance.

**Results**

**PANDAR expression is down-regulated in human lung cancer tissues**

To clarify the roles of PANDAR in NSCLC development, we explored the PANDAR expression status in tissues and found the expression of PANDAR in cancer tissues was downregulated compared to normal tissues ($P < 0.05$) (Fig. 1A). Meanwhile, the expression of autophagy related gene BECN1 mRNA expression was assayed and found that the BECN1 mRNA expression in cancer tissues was remarkably lower than that in normal tissues ($P < 0.01$) (Fig. 1B). Importantly, a positive association was observed between PANDAR and BECN1 in lung cancer tissues ($r = 0.789, P < 0.001$) (Fig. 1C). It demonstrated PANDAR may be associated with BECN1 gene in NSCLC.

**Associations between PANDAR expression and lung cancer progression**

According to the expression status of IncRNA PANDAR in tissues, it can be divided into “High” or “Low” expression group. As listed in Table 1, the levels of PANDAR expression was notable difference at TNM stages ($P = 0.001$), and lower status of PANDAR expression were observed at advanced T status (T3 + T4) than those with early T status (T1 + T2) ($P = 0.001$). Low expression of PANDAR was related to risk of lung cancer progression when merged the two characteristics. However, no other association was observed.

**PANDAR expression status in cell lines**

To determine the function of PANDAR in NSCLC, we analyzed the expression levels of PANDAR in human NSCLC and 16HBE cells. Fig. 1D revealed that the expression of PANDAR were
markedly downregulated in NSCLC cells (L78, PC9, 95D, NCI-H460 and A549) compared with 16HBE (P < 0.05). Based on the qRT-PCR results, we selected two representative cells (PC9 and A549) for subsequent cell functional experiments in vitro.

**Subcellular fractionation location**

To investigate the cellular localization of PANDAR, we fractionated PC9 and A549 into nuclear and cytoplasmic fractions. The results revealed that PANDAR was strongly enriched in the nuclear fraction of both PC9 and A549 cells (P < 0.05) (Fig. 1E), thus indicating PANDAR plays a regulatory role at the transcriptional levels.

**Upregulated PANDAR increases the expression of BECN1**

To determine the function of PANDAR, we evaluated the effects of PANDAR overexpression. The qRT-PCR results manifested PANDAR expression was increased both in PC9 and A549 cells after transfection with pEZ-Lv206-PANDAR (P<0.05) (Fig. 2A, 2B). Moreover, qRT-PCR results revealed the expression levels of BECN1 mRNA were increased when PANDAR was overexpressed compared with the pEZ-Lv206-control in PC9 and A549 cells (P < 0.05) (Fig. 2C). To further show the impact of PANDAR on BECN1 mRNA expression, western blot analysis was used to detect the expression levels of Beclin1 protein and the results exhibited the same trend (Fig. 2D).

---

**Figure 1. PANDAR expression is down-regulated in human lung cancer tissues and cell lines.** (A) The analysis of the PANDAR expression levels was performed in 276 pairs of lung cancer tissues by qRT-PCR and normalized to β-actin expression. The expression of PANDAR in lung cancer tissues is lower than those in non-tumorous tissues. (B) Comparing differences in the expression levels of BECN1 between tumor and corresponding normal tissues (n=276). (C) Positive correlation between PANDAR and BECN1 mRNA expression levels in 276 pairs of lung cancer tissue samples (r=0.789, P<0.001). (D) Levels of PANDAR in NSCLC cell lines and the normal pneumocyte cell line 16HBE. Mean ± SD represents three independent experiments (P < 0.05). (E) PANDAR nuclear localization, as identified using qRT-PCR in fractionated PC9 and A549 cell lines. GAPDH was used as a cytosol marker and U6 was used a nucleus marker. Mean ± SD represents three independent experiments (P < 0.05).
autophagy activation in NSCLC. It was suggested that upregulated PANDAR contributes to protein compared with control (Fig. 2F). These data

**Small Cell Lung Cancer**

**Adenocarcinoma**

**M status**

**T status**

**T3**

**N3**

**D**

**P**

**Table I. The relationship between PANDAR expression and clinicopathological features of NSCLC**

| Characteristics                      | Southern Samples, N (%) | **p*** | Eastern Samples, N (%) | **p*** | Total, N (%) | **p*** |
|--------------------------------------|-------------------------|--------|------------------------|--------|--------------|--------|
| Age                                  |                         |        |                        |        |              |        |
| <60                                  | 72(68.6)                | 0.486  | 32(62.7)               | 0.176  | 104(66.7)    | 0.155  |
| ≥60                                  | 49(63.6)                |        | 21(48.8)               |        | 70(58.3)     |        |
| Gender                               |                         |        |                        |        |              |        |
| Female                               | 37(71.2)                | 0.259  | 15(57.1)               | 0.861  | 53(66.3)     | 0.434  |
| Male                                 | 81(62.3)                |        | 39(50.1)               |        | 120(61.2)    |        |
| Family History                       |                         |        |                        |        |              |        |
| No                                   | 94(58.4)                | 0.758  | 49(58.3)               | 0.477  | 143(58.4)    | 0.512  |
| Yes                                  | 13(61.9)                |        | 7(70.0)                |        | 20(64.5)     |        |
| Smoking                              |                         |        |                        |        |              |        |
| No                                   | 31(46.3)                | 0.181  | 19(63.3)               | 0.244  | 50(51.5)     | 0.062  |
| Yes                                  | 65(56.5)                |        | 38(52.1)               |        | 113(63.1)    |        |
| Drinking                             |                         |        |                        |        |              |        |
| No                                   | 69(50.4)                | 0.261  | 38(52.1)               | 0.425  | 107(51.0)    | 0.170  |
| Yes                                  | 27(60.0)                |        | 13(61.9)               |        | 40(60.6)     |        |
| TNM stage                            |                         |        |                        |        |              |        |
| I+II                                 | 38(53.5)                | 0.031  | 17(58.6)               | 0.019  | 55(55.0)     | 0.001  |
| III+IV                               | 77(69.4)                |        | 53(81.5)               |        | 130(73.9)    |        |
| T status                             |                         |        |                        |        |              |        |
| T1+T2                                | 53(51.0)                | 0.034  | 28(62.2)               | 0.009  | 81(54.4)     | 0.001  |
| T3+T4                                | 52(66.7)                |        | 42(85.7)               |        | 94(74.0)     |        |
| N status                             |                         |        |                        |        |              |        |
| N0                                   | 41(62.1)                | 0.822  | 23(53.5)               | 0.193  | 64(58.7)     | 0.318  |
| N1+N2+N3                             | 74(63.8)                |        | 34(66.7)               |        | 108(64.7)    |        |
| M status                             |                         |        |                        |        |              |        |
| M0                                   | 81(62.8)                | 0.588  | 39(65.0)               | 0.250  | 120(63.5)    | 0.256  |
| M1                                   | 31(58.5)                |        | 18(52.9)               |        | 49(56.3)     |        |
| Histological Classification          |                         |        |                        |        |              |        |
| Adenocarcinoma                       | 47(54.7)                | 0.737  | 26(63.4)               | 0.831  | 73(57.5)     | 0.900  |
| Squamous Carcinoma                   | 28(54.9)                | 0.754  | 17(54.8)               |        | 45(54.9)     |        |
| Large Cell Lung Cancer               | 2(33.3)                 |        | 4(80.0)                |        | 6(34.5)      |        |
| Small Cell Lung Cancer               | 10(52.6)                | 0.754  | 5(62.5)                |        | 15(55.6)     |        |
| Others†                              | 13(65.0)                |        | 6(66.7)                |        | 19(65.5)     |        |

* Large cell carcinoma, small cell carcinoma, and hybrid or undifferentiated carcinoma; † Pearson χ².

**Overexpression of PANDAR induces autophagy levels in NSCLC**

To explore the mechanisms of PANDAR in regulating NSCLC progression, we investigated whether PANDAR regulated BECN1 mRNA signals, focusing on autophagy. When cell autophagy was stimulated, GFP-LC3 redistributed from a diffuse cytoplasmic pattern to form punctate structures that label preautophagosomal and autophagosomal membranes. Results showed that representative fluorescent microscopy images of GFP-LC3 endogenous punctate structures treated with pEZ-Lv206-PANDAR were more than control groups in PC9 and A549 cells. The fluorescence microscopy analysis revealed that PANDAR overexpression increased autophagy levels (Fig. 2E). Western blot analysis further illustrated that PANDAR overexpression led to a markedly increase of LC3-II protein compared with control (Fig. 2F). These data suggested that upregulated PANDAR contributes to autophagy activation in NSCLC.

**Upregulated PANDAR inhibits cell proliferation by activating autophagy**

To discuss the roles of PANDAR in regulating proliferation by autophagy, PC9 and A549 were treated with pEZ-Lv206-PANDAR or control. The CCK8 assay illustrated the upregulated PANDAR inhibited the proliferation in comparison to control among PC9 and A549 (Fig. 3A). Therefore, we concluded that the upregulated PANDAR may inhibit NSCLC cells proliferation by activating autophagy levels.

**Hoechst 33258**

To evaluate cell apoptotic status, morphological examinations were performed. We observed chromatin condensation in the PC9 and A549 with pEZ-Lv206-PANDAR or control respectively with Hoechst 33258. The nucleus of PC9 and A549 treated with pEZ-Lv206-PANDAR showed the occurrence of apoptosis in comparison with that of control (Fig. 3B). The results revealed upregulated PANDAR could promote NSCLC apoptosis.
Figure 2. The relationship between lncRNA PANDAR and BECN1 mRNA. (A) After transfecting pEZ-LV206-PANDAR or pEZ-LV206-control, we could preliminary judge the transfection efficiency of plasmid by fluorescence microscope. (B) PC9 and A549 cells were treated with pEZ-LV206-PANDAR or pEZ-LV206-control, and PANDAR expression was assayed by qRT-PCR. (C) qRT-PCR results showed that PANDAR overexpression resulted in an increase of the BECN1 mRNA expression levels in PC9 and A549 cells. (D) Western blot analysis of Beclin1 protein was performed at 72h. The results are presented as the Mean ± SD (*P<0.05). (E) The endogenous punctate structures represented relative autophagy levels by detecting fluorescence images of PANDAR and GFP-LC3 after transfection. (F) Western blot analysis was applied to elucidate the expression levels of LC3-II protein (autophagy marker). Data are representative of three independent experiments.

Figure 3. PANDAR overexpression inhibited proliferation and promoted apoptosis. (A) The roles of PANDAR in the regulation of cell proliferation. PC9 and A549 cells were treated with pEZ-Lv206-PANDAR or pEZ-Lv206-control. Cell proliferation was assayed by using CCK-8 according to the manufacturer’s protocol. Means±SD were shown (n=5). *P<0.05, **P<0.01 (vs.control). (B) Hoechst 33258 morphological examination of PANDAR promoting apoptosis. Typical apoptotic form after treating with pEZ-Lv206-PANDAR. Data are representative of three independent experiments. (C) Translocation of GFP-BECN1 treated with apoptosis promoter EBSS. PC9 and A549 cells transiently co-expressing GFP-BECN1 and DsRed-Mito. Translocation of GFP-BECN1 was performed by fluorescence microscopy. Control cells without GFP-BECN1 translocation over time. PC9 and A549 cells treated with EBSS, GFP-BECN1 translocated to mitochondria noticeably when cell apoptosis occurred. Data are representative of three independent experiments.
Detection of Beclin1 release during PANDAR-induced apoptosis

In order to understand this apoptotic pathway, we further observed the release of Beclin1 protein from mitochondria to the cytoplasm in PC9 and A549 co-expressed with DsRed-Mit and GFP-Beclin1. Using fluorescence microscope and subcellular fractionation methods, the pattern of GFP-Beclin fluorescence treated with EBSS was showed it was no difference from that of DsRed-Mit (Fig. 3C). The confocal images authenticated the distribution of GFP-Beclin1 fusion protein was in the mitochondria when cell apoptosis occurred.

Discussion

Recent studies have found IncRNA PANDAR interacted with transcription factor in normal human embryonic lung fibroblasts to inhibit the expression of pro-apoptotic genes. Subsequently, Han et al. confirmed that IncRNA PANDAR is closely related to the prognosis in lung cancer, which can affect cell apoptosis by regulating Bcl-2. Bcl-2 was an anti-apoptotic protein, and could regulate cell autophagy levels by which interacted with Beclin1 to form Beclin1-Bcl-2 complex through BH3 domain. Furthermore, we have confirmed that the Beclin1 expression was decreased in malignant transformed 16HBE cells, indicating that autophagy plays significant role in lung cancer. Therefore, we deduced IncRNA PANDAR should be associated with BECN1, and PANDAR involved in the development of lung cancer by regulating autophagy pathway in lung cancer. The PANDAR more likely functions as a novel tumor suppressor.

In this study, we concluded the expression of IncRNA PANDAR in 276 lung cancer tissues were lower than that in the matched normal lung tissues. The high expression of PANDAR was significantly associated with TNM stage and primary tumor depth of invasion. While BECN1 was in a lower expression in lung cancer tissues than in normal lung tissues, there was a positive correlation relationship between PANDAR and BECN1. In order to further illustrate the relationship between IncRNA PANDAR and BECN1, we established pEZ-Lv206-mediated overexpression of PANDAR in PC9 and A549 cells. We found overexpressed PANDAR would result in the expression levels of BECN1 gene and its corresponding protein Beclin1 were both increased obviously by qRT-PCR and Western Blot experiments. These results suggested that IncRNA PANDAR can promote BECN1 expression at the transcription and translation levels in lung cancer. At present, studies have revealed BECN1 was one of the most important genes involved in autophagy. Therefore, we investigated the relationship between IncRNA PANDAR and autophagy in lung cancer by PANDAR and GFP-LC3 plasmids co-transfection experiments, and the results demonstrated the GFP-LC3 endogenous punctate structures increased significantly in overexpressed PANDAR groups compared with control groups. In addition, the autophagy marker LC3-II protein expression levels were also increased when PANDAR expression up-regulated, and this further validated the results of co-transfection experiments indicating that IncRNA PANDAR could increase autophagy levels in lung cancer cells. The possible mechanism was PANDAR involved in autophagy activation by up-regulating the expression levels of BECN1. To elucidate the biological roles of IncRNA PANDAR in the regulation of autophagy in NSCLC, cell viability assays were used and results showed optical density at PANDAR overexpression group was lower than control. These suggested that increased expression of IncRNA PANDAR could significantly inhibit the growth and proliferation of lung cancer cells and IncRNA PANDAR maybe inhibit the progression of lung cancer through autophagy pathway.

Many studies have confirmed that the process of autophagy and apoptosis occurred in tumor cells at the same time. Hoechst 33258 experiments were used to elucidate the relationship between IncRNA PANDAR and apoptosis in lung cancer cells, and the results showed in comparision with control group, the number of apoptotic lung cancer cells increased in overexpressed PANDAR group. So, we concluded that IncRNA PANDAR regulated the development of lung cancer involved in not only autophagy pathway but also apoptosis pathway. Mitochondrial apoptosis is one of the most important apoptotic pathways. Some researchers have found that various apoptotic stimulus signals can induce Bcl-2 family apoptosis related proteins with BH3 domain and regulate cell apoptosis through mitochondrial pathway. Beclin1 and Bcl-2 family proteins both have BH3 receptor domain, so we speculated that IncRNA PANDAR would promote the apoptosis of lung cancer cells in mitochondria pathway by increasing Beclin1 expression levels. In order to verify the above hypothesis, we used fluorescence microscope and subcellular fractionation methods to detect the location of Beclin1 release during PANDAR-induced apoptosis in NSCLC. The results showed that Beclin1 protein appeared punctate aggregation and its location was indistinguishable from DsRed-Mit when the PC9 and A549 cells occurred apoptosis. These results indicated PANDAR promoted cell apoptosis through mitochondrial pathway in the development of NSCLC. The possible mechanism was the
up-regulated Beclin1 protein went into mitochondria, and affected the expression levels of apoptosis-related protein, such as Bax, thereby triggering apoptotic signals and promoting cell apoptosis.

In conclusion, this study has confirmed that lncRNA PANDAR can affect the development of lung cancer by regulating the expression of BECN1 gene. Further studies found PANDAR involved in autophagic regulation at the levels of transcription and translation, which led to the loss of the survival advantage of tumor cells, thus inhibited cell growth and proliferation. While, we didn’t perform related experiments to test the invasion and migration ability of PANDAR in vitro and we will continue to examine other biological functions about lncRNA PANDAR in the future. In addition, PANDAR can promote cell apoptosis through the mitochondrial pathway. These results concluded lncRNA PANDAR can play essential roles in the development of lung cancer through autophagy and apoptosis pathways.

Abbreviations
NSCLC: Non-small cell lung cancer; PANDAR: promoter of CDKN1A antisense DNA damage-activated RNA; qRT-PCR: quantitative real-time PCR; lncRNA: long non-coding RNA; 16HBE: normal bronchial epithelial cell line; FBS: fetal bovine serum; RIPA: radioimmunoprecipitation assay; CCK8: Cell Counting Kit-8; OD: Optical density; TNM: tumor-node-metastases; EBSS: Earle’s balanced salt solution.

Acknowledgments
This study was supported by the National Natural Scientific Foundation of China grants (81473040, 81673267, 81872694, 81402753, 81672303, 81871876, 81803325); Science and Technology Bureau of Jiaxing (2019AD32218); National Natural Science Foundation of Guangdong (2016A030313567); Scientific Research Foundation of Guangzhou Municipal Colleges and Universities for Yangcheng Scholar (12A010D); Science and Technology Program of Guangzhou (201607010035); Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2017BT01S155); Science Foundation for Distinguished Young Scholars in Jiangsu (BK20160008); Guangdong Provincial Major Projects Grants (2014KZDXM046); Guangdong Education Bureau Characteristic Innovation Project Grants (2015KTSCX116); and Guangzhou Science and Technology Program Pearl River Nova Projects grants (201710010049).

Competing Interests
The authors have declared that no competing interest exists.

References
1. Pan Z, Liu L, Nie W, et al. Long non-coding RNA AGER-1 functionally upregulates the innate immunity gene AGER and approximates its anti-tumor effect in lung cancer. Mol Carcinog. 2018; 57: 305-18.
2. Wu D, Yang B, Chen J, et al. Upregulation of long non-coding RNA RABIA-2 induces FGFl1 expression worsening lung cancer prognosis. Cancer Lett. 2018; 438: 116-25.
3. Liu Z, Cao H, Shi Y, et al. KIAA1211 plays an oncogenic role in human non-small cell lung cancer. J Cancer. 2019; 10: 6747-53.
4. Abdelhamed S, Ogura K, Yokoyama S, et al. AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells. J Cancer. 2016; 7: 1579-86.
5. Marsh D, Draeger JM. Autophagy in mammalian neurodevelopment and implications for childhood neurological disorders. Neuroscience Lett. 2019; 697: 29-33.
6. Lee CH, Lin ST, Liu JI, et al. Salmonella induces autophagy in melanoma by the down-regulation of AKT/mTOR pathway. Gene Ther. 2014; 21: 309-16.
7. Ding WX, Chen X, Yin XM. Tumor cells can evade dependence on autophagy through adaptation. Biochem Biophys Res Commun. 2012; 425: 684-90.
8. You X, Xu L, et al. Overexpression of lncRNA FZJ-AS1 is associated with advanced clinical stages and family history of cancer in patients with NSCLC. Pathol Res Pract. 2018; 214: 857-61.
9. Guttman M, Donaghey J, Carey BW, et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011; 477: 295-300.
10. Yang B, Zhang L, Cao Y, et al. Overexpression of IncRNA IGFBP4-1 reprograms energy metabolism to promote lung cancer progression. Mol Cancer. 2017; 16: 154.
11. Gupta RA, Shah N, Wang KC, et al. Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010; 464: 1071-6.
12. Liu KH, Li W, Liu XH, et al. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer. 2013; 13: 461.
13. Liu M, Zhang H, Li Y, et al. HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer. Cancer Sci. 2018; 109: 2717-33.
14. Yang L, Wu D, Chen J, et al. A functional CNVR_3425.1 damping lincRNA FENDRR increases lifetime risk of lung cancer and COPD in Chinese. Carcinogenesis. 2018; 39: 347-59.
15. Zhao J, Liu Y, Zhang W, et al. Long non-coding RNA Linc00152 is involved in cell cycle arrest, apoptosis, epithelial to mesenchymal transition, cell migration and invasion in gastric cancer. Cell Cycle. 2015; 14: 3112-23.
16. Yang J, Lin J, Liu T, et al. Analysis of IncRNA expression profiles in non-small cell lung cancers (NSCLC) and their clinical subtypes. Lung Cancer. 2014; 85: 1071-6.
17. Hu KH, Li W, Liu XH, et al. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer. 2013; 13: 461.
18. Liu M, Zhang H, Li Y, et al. HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer. Cancer Sci. 2018; 109: 2717-33.
19. Yang L, Wu D, Chen J, et al. A functional CNVR_3425.1 damping lincRNA FENDRR increases lifetime risk of lung cancer and COPD in Chinese. Carcinogenesis. 2018; 39: 347-59.
20. Zhao J, Liu Y, Zhang W, et al. Long non-coding RNA Linc00152 is involved in cell cycle arrest, apoptosis, epithelial to mesenchymal transition, cell migration and invasion in gastric cancer. Cell Cycle. 2015; 14: 3112-23.
21. Yang J, Lin J, Liu T, et al. Analysis of IncRNA expression profiles in non-small cell lung cancers (NSCLC) and their clinical subtypes. Lung Cancer. 2014; 85: 110-5.
22. Lu Z, Li Y, Che Y, et al. The TGFβ-induced IncRNA TBLA promotes non-small cell lung cancer progression in vitro and in vivo via cis-regulating HGAL and activating S100A7/JAB1 signaling. Cancer Lett. 2018; 432: 156-68.
23. Huang T, Wang Y, Lin MF, et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet. 2011; 43: 621-9.
24. Han L, Zhang EB, Yin DD, et al. Low expression of long noncoding RNA PANDAR predicts a poor prognosis of non-small cell lung cancer and affects cell apoptosis by regulating Bcl-2. Cell Death Dis. 2015; 6: e1665.
25. Pattinighe S, Tassa A, Qu X, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005; 122: 927-39.
26. Zhang L, Yang L, Liu JC. Role of autophagy in the malignant transformation of 16HBE cells by anti-BFDE. Chinese Journal of Cancer Prevention and Treatment. 2012; 19: 885-7.